| Literature DB >> 20434771 |
Stéphanie Haïat1, Zora Marjanovic, Simona Lapusan, Anne Vekhoff, Bernard Rio, Elise Corre, Sophie Dimicoli, Pierre Hirsch, Jean-Pierre Marie, Ollivier Legrand.
Abstract
Adolescents ALL have a better outcome when treated with pediatric protocol compared to adult protocol. We have tested the feasibility of pediatric protocol to treat 40 consecutive adults ALL. DFS and OS were 73±7%, and 72±7%, and were significantly longer in patients under 40 yo (81±9% vs 51±15%, p=0.05 [DFS] and 83±7.8% vs 45±15%, p=0.003 [OS], respectively) or cortico/chemo-sensitive (86±9% vs 36±16%, p=0.001 [DFS] and 95±4.4% vs 28±13%, p<0.0001 [OS]) than in other patients. Overall tolerance was acceptable. We have shown the feasibility of using this unmodified pediatric protocol to treat adult with ALL up to 40 years.Entities:
Mesh：
Year: 2011 PMID： 20434771 DOI： 10.1016/j.leukres.2010.04.002
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156